Table 1.
Demographic and Clinical Characteristics of the Study Cohort
| Clinical Features | All Patients (N=268) |
|---|---|
| Sex (male) | 192 (71.64%) |
| Age (years) | 57.5 (46–71) |
| Mechanical ventilation | 189 (70.52%) |
| Vasoactive agents | 144 (53.73%) |
| Admission to ICU | 182 (67.91%) |
| APACHE II | 19.94 (13.17–25.91) |
| Comorbidities | |
| Cardiovascular and cerebrovascular diseases | 169 (63.06%) |
| Respiratory disease | 226 (84.33%) |
| Kidney disease | 120 (44.78%) |
| Liver disease | 67 (25.00%) |
| Diseases of digestive system | 52 (19.40%) |
| Nutritional disease | 34 (12.69%) |
| Diabetes mellitus | 44 (16.42%) |
| Infection site | |
| Respiratory tract | 254 (94.78%) |
| Blood | 84 (31.34%) |
| Urinary system | 29 (10.82%) |
| Intracranial | 17 (6.34%) |
| Digestive tract | 30 (11.19%) |
| Skin and soft tissue | 21 (7.84%) |
| Pathogenic bacteria (CR-GNB) | |
| Acinetobacter baumannii | 185 (69.03%) |
| Klebsiella pneumoniae | 116 (43.28%) |
| Pseudomonas aeruginosa | 64 (23.88%) |
| E. coli or E. cloacae | 8 (2.99%) |
| Multiple site infection | 119 (44.40%) |
| Number of patients with CR-GNB >1 | 65 (24.30%) |
| Antimicrobial susceptibility | |
| Tigecycline MIC >2 (mg/L) | 229/278 (82.37%) |
| Polymyxin MIC >2 (mg/L) | 9/370 (2.43%) |
| Previous carbapenem treatment time (days) | 5.00 (0.45–11.36) |
| Previous tigecycline treatment time (days) | 0.67 (0.00–7.27) |
| Previous use of carbapenem | 177 (66.04%) |
| Previous use of tigecycline FG | 109 (40.70%) |
Notes: Vasoactive drugs include norepinephrine, dopamine, epinephrine, isoproterenol, phentolamine, and nitroglycerin; the time of previous carbapenems and tigecycline use was defined as the time before PMB was used in this hospitalization.
Abbreviations: ICU, Intensive Care Unit; APACHE II, Acute Physiology and Chronic Health Evaluation II; CR-GNB, Carbapenem-resistant Gram-negative Bacteria; MIC, minimum inhibitory concentration.